Interstitial lung disease: progress and problems

S J Bourke, S J Bourke

Abstract

Interstitial lung disease involves all areas of medicine as it often occurs in patients with comorbidities or as a consequence of systemic diseases and their treatment. Typically the physician is faced with a breathless patient, a diffusely abnormal chest radiograph, and a wide differential diagnosis. Progress has been made in using high resolution computed tomography as the key investigation in characterising the pattern and extent of the disease. Bronchoalveolar lavage is particularly important in excluding infection as a cause of diffuse lung infiltrates. Surgical lung biopsies have led to a new classification system for the range of histopathological patterns of disease that were previously known by the collective term cryptogenic fibrosing alveolitis. Problems persist in deciding when a surgical lung biopsy is clinically justified, in understanding the pathogenesis of these diseases, and in finding more effective treatments.

Conflict of interest statement

Conflicts of interest: none.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2585700/bin/pj46417.f1.jpg
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2585700/bin/pj46417.f2.jpg
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2585700/bin/pj46417.f3.jpg

References

    1. Cushley M J, Davison A G, DuBois R al The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults: British Thoracic Society recommendations. Thorax. 1999;54(suppl 1)
    1. King T E. Clinical advances in the diagnosis and therapy of interstitial lung diseases. Am J Respir Crit Care Med 2005172268–279.
    1. DuBois T M, Costabel U. Diffuse lung disease: classification and diagnostic approach. In: Gibson GJ, Geddes DM, Costabel U, et al, eds. Respiratory medicine. London: Elsevier Science, 20031545–1556.
    1. Johnson I D A, Prescott R J, Chalmers J al British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 19975238–44.
    1. Joint statement of the American Thoracic Society and European Respiratory Society Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000161646–664.
    1. American Thoracic Society/European Respiratory Society International multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002165277–304.
    1. Ward P A, Hunninghake G W. Lung inflammation and fibrosis. Am J Resp Crit Care Med 1998157s123–s129.
    1. Kennedy J I, Myers J L, Plumb V al Amiodarone pulmonary toxicity: clinical, radiologic and pathologic correlations. Arch Intern Med 198714750–55.
    1. Flaherty K R, King T E, Raghu al Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004170904–910.
    1. McLoud T. Role of high‐resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005172408–409.
    1. Lynch D A, Godwin J D, Safrin al High‐resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care 2005172488–493.
    1. Drent M, Jacobs J A, Wagenaar S S. Bronchoalveolar lavage. Eur Respir Mon 20001463–78.
    1. Langford C A, Hoffman G S. Wegener's granulomatosis. Thorax 199954629–637.
    1. Vasallo R, Ryu I H, Colby T al Pulmonary Langerhans cell histiocytosis. N Engl J Med 20003421969–1977.
    1. Seymour J F, Presneill J J. Pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2002166215–235.
    1. Fishbein M. To biopsy or not biopsy: assessing the role of surgical biopsy in the diagnosis of idiopathic pulmonary fibrosis. Chest 2005128s520–s525.
    1. Lacasse Y, Selman M, Costabel al Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003168952–958.
    1. Bourke S J, Dalphin J C, Boyd al Hypersensitivity pneumonitis: current concepts. Eur Respir J 200118(suppl 32)81–92.
    1. British Thoracic Society Guidelines on diagnostic flexible bronchoscopy. Thorax 200156(suppl 1)1–21.
    1. Lettieri C J, Veerappan G R, Helman D al Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 20051271600–1605.
    1. Wells A U. Histopathological diagnosis in diffuse lung disease: an ailing gold standard. Am J Respir Crit Care Med 2004170828–829.
    1. Hubbard R, Lewis S, Richards al Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996347284–289.
    1. Raghu G, Freudenberger T D, Yang al High prevalence of abnormal acid grastroesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 200627136–142.
    1. Steele M P, Speer M C, Loyd J al Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 20051721146–1152.
    1. Selman M, Pardo A, Barrera al Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006173188–198.
    1. Bouros D, Antoniou K M. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 200526693–702.
    1. Dermedts M, Behr J, Buhl al High‐dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 20053532229–2242.
    1. Myers J L, Veal C F, Shin M al Respiratory bronchioloitis causing interstitial lung disease: a clinicopathological study of six cases. Am Rev Respir Dis 1987135880–884.
    1. Mavridou D, Laws D. Respiratory bronchiolitis associated interstitial lung disease (RB‐ILD): a case of an acute presentation. Thorax 200459910–911.
    1. Swigris J J, Berry G J, Raffin T al Lymphoid interstitial pneumonia. Chest 20021222150–2164.
    1. Bellomo R, Finlay M, McLaughlin al Clinical spectrum of cryptogenic organising pneumonitis. Thorax 199146554–558.
    1. Riha R L, Duhig E E, Clarke B al Survival of patients with biopsy‐proven usual interstitial pneumonia and non‐specific interstitial pneumonia. Eur Respir J 2002191114–1118.
    1. Wells A U. Lung disease in association with connective tissue diseases. Eur Respir Mon 200014137–164.
    1. Douglas W W, Tazelaar H D, Hartman T al Polymyositis‐dermatomyositis‐associated interstitial lung disease. Am J Respir Crit Care Med 20011641182–1185.
    1. Owens G R, Fallansbee W P. Cardiopulmonary manifestations of systemic sclerosis. Chest 198791118–127.
    1. Camus P, Gibson G J. Iatrogenic respiratory disease. In: Gibson GJ, Geddes DM, Costabel U, et al, eds. Respiratory medicine. London: Elsevier Science, 2003764–806.
    1. Adams P C, Gibson G J, Morley A al Amiodarone pulmonary toxicity: clinical and subclinical features. Q J Med 198659449–471.
    1. White D A, Stover D E. Severe bleomycin‐induced pneumonitis: clinical features and response to corticosteroids. Chest 198486723–728.
    1. British Thoracic Society Recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti‐TNF‐alpha treatment. Thorax 200560800–805.
    1. Colombel J F, Loftus E V, Tremaine W al The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 20041261–23.
    1. Ostor A J, Crisp A J, Somerville M al Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 20043291266–1268.
    1. Riegert‐Johnson D L, Godfrey J A, Myers J al Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflammatory Bowel Disease 20028186–191.
    1. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis. Rheumatology 200544157–163.
    1. Bourke S J, Boyd G. Pigeon fancier's lung. BMJ 199731570–71.
    1. Nemery B, Bast A, Behr al Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J 200118(suppl 32)30–42.
    1. Ohtani Y, Saiki S, Kitaichi al Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 200560665–671.
    1. Perez‐Padilla R, Salas J, Chapela al Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 199314849–53.
    1. Bourke S J, Anderson K, Lynch al Chronic simple bronchitis in pigeon fancier's. Chest 198995598–601.
    1. Bourke S J, Carter R, Anderson al Obstructive airways disease in non‐smoking subjects with pigeon fancier's lung. Clin Expt Allergy 198919629–632.
    1. Kokkarinen J I, Tukiainen H O, Terho E O. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 19921453–5.
    1. American Thoracic Society Statement on sarcoidosis. Am J Respir Crit Care Med 1999160736–755.
    1. Martin W J, Iannuzzi M C, Gail D al Future directions in sarcoidosis research. Am J Respir Crit Care Med 2004170567–571.
    1. Zajicek J P, Scolding N J, Foster al Central nervous system sarcoidosis‐diagnosis and management. Q J Med 199991103–117.
    1. Ward K, O'Connor C, Odlum al Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989446–12.
    1. Gibson G J, Prescott R J, Muers M al British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax 199651238–247.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe